Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Lagging the benchmark's 10.82% as AI-driven concentration dominated markets. Financials and health care detracted on capital markets weakness and cost inflation concerns.
Full Quick Take
Lagging the benchmark's 10.82% as AI-driven concentration dominated markets. Financials and health care detracted on capital markets weakness and cost inflation concerns.
Baillie Gifford's International Growth strategy exploits market short-termism to build a diversified portfolio of high-quality growth companies positioned for AI transformation and structural change.
Full Quick Take
Baillie Gifford's International Growth strategy exploits market short-termism to build a diversified portfolio of high-quality growth companies positioned for AI transformation and structural change.
Brandes International Equity underperformed in Q2 2026 as AI-driven technology concentration dominated markets. The manager trimmed semiconductor winners and maintains conviction in mission-critical enterprise software despite near-term pressure.
Full Quick Take
Brandes International Equity underperformed in Q2 2026 as AI-driven technology concentration dominated markets. The manager trimmed semiconductor winners and maintains conviction in mission-critical enterprise software despite near-term pressure.
Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness.
Full Quick Take
Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness.
Matching the market despite avoiding AI beneficiaries. The manager views AI infrastructure spending as unsustainable, with the six largest spenders approaching $1trn annually requiring unrealistic returns.
Full Quick Take
Matching the market despite avoiding AI beneficiaries. The manager views AI infrastructure spending as unsustainable, with the six largest spenders approaching $1trn annually requiring unrealistic returns.
Concentrated global growth fund underperformed significantly in Q1 2026 despite strong individual company fundamentals. Manager maintains high conviction in technology leaders like Arm Holdings benefiting from AI adoption and Tesla's EV/autonomy evolution.
Full Quick Take
Concentrated global growth fund underperformed significantly in Q1 2026 despite strong individual company fundamentals. Manager maintains high conviction in technology leaders like Arm Holdings benefiting from AI adoption and Tesla's EV/autonomy evolution.
Arquitos targets liquidating biotechs trading below cash value and patent-driven pharmaceutical plays. Manager most bullish ever on Liquidia Corporation, expecting $70-140 per share regardless of pending patent decision.
Full Quick Take
Arquitos targets liquidating biotechs trading below cash value and patent-driven pharmaceutical plays. Manager most bullish ever on Liquidia Corporation, expecting $70-140 per share regardless of pending patent decision.
Fund outperformed with 2.4% gain versus S&P 500's 4.3% decline in volatile Q1 2026. Iran conflict drove energy sector strength while AI disruption pressured software holdings.
Full Quick Take
Fund outperformed with 2.4% gain versus S&P 500's 4.3% decline in volatile Q1 2026. Iran conflict drove energy sector strength while AI disruption pressured software holdings.
The fund underperformed in October despite strong pharmaceutical holdings GSK and AstraZeneca raising guidance. Technology holdings faced headwinds with leadership changes and margin pressure.
Full Quick Take
The fund underperformed in October despite strong pharmaceutical holdings GSK and AstraZeneca raising guidance. Technology holdings faced headwinds with leadership changes and margin pressure.
Strong Q3 performance driven by healthcare winners UCB and Sandoz, plus semiconductor recovery positioning. Defense and AI infrastructure themes supported by quality holdings.
Full Quick Take
Strong Q3 performance driven by healthcare winners UCB and Sandoz, plus semiconductor recovery positioning. Defense and AI infrastructure themes supported by quality holdings.
Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities.
Full Quick Take
Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities.
The portfolio underperformed in Q3 2025 as the market favored high-beta momentum stocks and commodity miners. Harding Loevner remains anchored in its long-term quality-compounder strategy, adding to resilient IT services and health care equipment holdings on weakness.
Full Quick Take
The portfolio underperformed in Q3 2025 as the market favored high-beta momentum stocks and commodity miners. Harding Loevner remains anchored in its long-term quality-compounder strategy, adding to resilient IT services and health care equipment holdings on weakness.
VELA International outperformed in Q3 with 7.43% returns while maintaining 9.5% defensive cash position. Added healthcare and consumer names at attractive valuations amid tariff uncertainty.
Full Quick Take
VELA International outperformed in Q3 with 7.43% returns while maintaining 9.5% defensive cash position. Added healthcare and consumer names at attractive valuations amid tariff uncertainty.
Healthcare holdings faced sector headwinds from administration policy uncertainty. Portfolio trades at widest discount to intrinsic value since mid-2022.
Full Quick Take
Healthcare holdings faced sector headwinds from administration policy uncertainty. Portfolio trades at widest discount to intrinsic value since mid-2022.
Global growth fund underperformed in Q1 2025 with -3.35% returns versus -1.32% benchmark. Strong performance from MercadoLibre, Alibaba, and Novartis offset weakness in Tesla, Alphabet, and Amazon.
Full Quick Take
Global growth fund underperformed in Q1 2025 with -3.35% returns versus -1.32% benchmark. Strong performance from MercadoLibre, Alibaba, and Novartis offset weakness in Tesla, Alphabet, and Amazon.
Strong Q1 performance driven by European small-cap exposure, outperforming benchmark by 484 basis points. Portfolio activity included strategic additions in luxury fashion, pharmaceutical packaging, and cloud services while exiting positions at fair value.
Full Quick Take
Strong Q1 performance driven by European small-cap exposure, outperforming benchmark by 484 basis points. Portfolio activity included strategic additions in luxury fashion, pharmaceutical packaging, and cloud services while exiting positions at fair value.
Sound Shore's value strategy faced headwinds in Q1 with a 1.9% decline as healthcare regulatory concerns and economic uncertainty weighed on holdings. The portfolio trades at an attractive 11.0x forward earnings versus 20.1x for the S&P 500.
Full Quick Take
Sound Shore's value strategy faced headwinds in Q1 with a 1.9% decline as healthcare regulatory concerns and economic uncertainty weighed on holdings. The portfolio trades at an attractive 11.0x forward earnings versus 20.1x for the S&P 500.
Strong quarter driven by European bank earnings resilience and Chinese tech recovery, particularly Alibaba's accelerating e-commerce growth. Portfolio maintains cyclical overweights in financials while adding defensive healthcare and staples exposure.
Full Quick Take
Strong quarter driven by European bank earnings resilience and Chinese tech recovery, particularly Alibaba's accelerating e-commerce growth. Portfolio maintains cyclical overweights in financials while adding defensive healthcare and staples exposure.
The Fund capitalized on risk contango conditions by rotating towards quality defensive pharmaceutical stocks while maintaining overweight China and Europe positions. Strong Chinese technology performance and defensive positioning protected capital during March tariff volatility.
Full Quick Take
The Fund capitalized on risk contango conditions by rotating towards quality defensive pharmaceutical stocks while maintaining overweight China and Europe positions. Strong Chinese technology performance and defensive positioning protected capital during March tariff volatility.
Itus Capital maintains defensive large cap positioning amid macro headwinds from declining market-linked tax revenues threatening government capex spending. Portfolio concentrated in market-leading banks, pharma, and consumer companies while avoiding government-dependent sectors.
Full Quick Take
Itus Capital maintains defensive large cap positioning amid macro headwinds from declining market-linked tax revenues threatening government capex spending. Portfolio concentrated in market-leading banks, pharma, and consumer companies while avoiding government-dependent sectors.
Arquitos outperformed in 2024 and manager expresses highest confidence ever in 2025 prospects. Concentrated small-cap portfolio focused on biotech catalysts including Finch's patent litigation upside and Liquidia's May FDA approval for superior inhaler technology.
Full Quick Take
Arquitos outperformed in 2024 and manager expresses highest confidence ever in 2025 prospects. Concentrated small-cap portfolio focused on biotech catalysts including Finch's patent litigation upside and Liquidia's May FDA approval for superior inhaler technology.
Underperforming the S&P 500 but achieving solid absolute returns. The fund has shifted toward value opportunities in small/mid-caps left behind in the rally.
Full Quick Take
Underperforming the S&P 500 but achieving solid absolute returns. The fund has shifted toward value opportunities in small/mid-caps left behind in the rally.
EdgePoint applies disciplined value investing globally, seeking misunderstood companies trading below intrinsic value. Recent successes include Fairfax Financial and SAP, both doubling as transformation stories played out.
Full Quick Take
EdgePoint applies disciplined value investing globally, seeking misunderstood companies trading below intrinsic value. Recent successes include Fairfax Financial and SAP, both doubling as transformation stories played out.
Sold About You and Interactive Brokers on valuation concerns, added Spanish pharma Rovi and German telecom United Internet. Ten-year investment horizon focuses on capable management, defensible business models, and deep value opportunities.
Full Quick Take
Sold About You and Interactive Brokers on valuation concerns, added Spanish pharma Rovi and German telecom United Internet. Ten-year investment horizon focuses on capable management, defensible business models, and deep value opportunities.
Ariel International Fund outperformed in Q3 2024 with a 7.56% return, driven by Chinese e-commerce and cybersecurity holdings benefiting from stimulus and strong fundamentals. The value-focused strategy targets misunderstood, undervalued international franchises.
Full Quick Take
Ariel International Fund outperformed in Q3 2024 with a 7.56% return, driven by Chinese e-commerce and cybersecurity holdings benefiting from stimulus and strong fundamentals. The value-focused strategy targets misunderstood, undervalued international franchises.
Aristotle International underperformed in Q2, swapping Novartis for Roche in pharmaceuticals while Cameco led on nuclear energy tailwinds. Consulting headwinds hurt Accenture despite strong AI bookings.
Full Quick Take
Aristotle International underperformed in Q2, swapping Novartis for Roche in pharmaceuticals while Cameco led on nuclear energy tailwinds. Consulting headwinds hurt Accenture despite strong AI bookings.
RS Large Cap Value outperformed by 300+ basis points in Q2 despite value's continued underperformance versus growth. Strong stock selection in Financials and Healthcare drove results.
Full Quick Take
RS Large Cap Value outperformed by 300+ basis points in Q2 despite value's continued underperformance versus growth. Strong stock selection in Financials and Healthcare drove results.
Aristotle Atlantic outperformed in Q4 through strong stock selection, particularly in AI-exposed Broadcom and restructuring Spirit AeroSystems. Added pharmaceutical leaders Eli Lilly and Vertex while exiting Bristol-Myers and PepsiCo.
Full Quick Take
Aristotle Atlantic outperformed in Q4 through strong stock selection, particularly in AI-exposed Broadcom and restructuring Spirit AeroSystems. Added pharmaceutical leaders Eli Lilly and Vertex while exiting Bristol-Myers and PepsiCo.
Aristotle Core Equity outperformed in Q4 2023 through strong stock selection, particularly in AI-beneficiary Broadcom and turnaround story Spirit AeroSystems. The fund rotated into pharmaceutical leaders Eli Lilly and Vertex while exiting Bristol-Myers and PepsiCo.
Full Quick Take
Aristotle Core Equity outperformed in Q4 2023 through strong stock selection, particularly in AI-beneficiary Broadcom and turnaround story Spirit AeroSystems. The fund rotated into pharmaceutical leaders Eli Lilly and Vertex while exiting Bristol-Myers and PepsiCo.
New positions in Agilent, Kroger, and Roche highlight the fund's focus on transformed companies facing temporary headwinds. Strong stock selection in financials and technology offset pharmaceutical disappointments, maintaining the fund's long-term outperformance track record.
Full Quick Take
New positions in Agilent, Kroger, and Roche highlight the fund's focus on transformed companies facing temporary headwinds. Strong stock selection in financials and technology offset pharmaceutical disappointments, maintaining the fund's long-term outperformance track record.
ClearBridge's international growth strategy suffered as value dramatically outperformed growth by 900+ basis points in Q3. Despite underperformance, managers maintain conviction in their disciplined approach across secular, structural, and emerging growth companies.
Full Quick Take
ClearBridge's international growth strategy suffered as value dramatically outperformed growth by 900+ basis points in Q3. Despite underperformance, managers maintain conviction in their disciplined approach across secular, structural, and emerging growth companies.
Australian activist fund targeting undervalued companies through governance engagement. Strong June performance led by Fleetwood's contracted revenue growth and new MFG campaign launch.
Full Quick Take
Australian activist fund targeting undervalued companies through governance engagement. Strong June performance led by Fleetwood's contracted revenue growth and new MFG campaign launch.
Maintaining long-term outperformance through focus on quality businesses with durable moats. New position in Japan's Ain Holdings capitalizes on pharmacy industry consolidation while increased Helical stake reflects opportunistic real estate investment.
Full Quick Take
Maintaining long-term outperformance through focus on quality businesses with durable moats. New position in Japan's Ain Holdings capitalizes on pharmacy industry consolidation while increased Helical stake reflects opportunistic real estate investment.
ClearBridge's value strategy navigated Q1 2023 banking turmoil by favoring large, diversified banks while opportunistically adding to healthcare positions including McKesson and Becton Dickinson.
Full Quick Take
ClearBridge's value strategy navigated Q1 2023 banking turmoil by favoring large, diversified banks while opportunistically adding to healthcare positions including McKesson and Becton Dickinson.